GlassScriptPhysician profile
Narayan S Tata
NPI 1881648962
$1,369.54
in general payments reported to CMS, 2019-2025
25 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $325 · 2022: $47.96 · 2023: $120 · 2024: $131 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electronic Waveform Lab, INC. | $266.28 | 2020 | |
| Collegium Pharmaceutical, INC. | $197.46 | 2022-2024 | Xtampza, Belbuca |
| Boston Scientific Corporation | $152.66 | 2019-2025 | General - Pain Management |
| Arbor Pharmaceuticals, INC. | $143.36 | 2019-2020 | |
| Si-Bone, INC. | $83.21 | 2019-2020 | |
| Daiichi Sankyo INC. | $77.20 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $57.94 | 2023 | Seglentis |
| Scilex Pharmaceuticals INC. | $55.19 | 2019 | |
| Pfizer INC. | $51.78 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.62 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $24.97 | 2025 | |
| Kaleo, INC. | $24.47 | 2019 | |
| Orthogenrx INC. | $20.47 | 2019 | |
| Valinor Pharma, LLC | $19.03 | 2025 | Movantik |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $15.69 | 2025 | Tirosint, Flector, Licart |
| Grt US Holding, INC. | $15.65 | 2022 | |
| Assertio Therapeutics, INC. | $14.90 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.45 | 2019 | |
| Fidia Pharma USA INC. | $13.83 | 2019 | |
| Biodelivery Sciences International, INC. | $13.81 | 2020 | |
| Azurity Pharmaceuticals, INC. | $13.59 | 2023 | Horizant |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.83 | 2020 | |
| Redhill Biopharma INC. | $11.35 | 2020 | |
| Shionogi INC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narayan Tata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.